The challenge of defining “ultra‐high‐risk” neuroblastoma
暂无分享,去创建一个
Gudrun Schleiermacher | Meredith S Irwin | John M Maris | Rochelle Bagatell | J. Maris | W. London | M. Hogarty | S. Cohn | R. Bagatell | G. Schleiermacher | D. Morgenstern | Daniel A Morgenstern | Wendy B London | Susan L Cohn | Andrew D Pearson | D. Valteau‐Couanet | Julie R. Park | Dominique Valteau-Couanet | Julie R Park | A. Pearson | M. Irwin | L. Moreno | Michael D Hogarty | Lucas Moreno
[1] Hiroyuki Shimada,et al. Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system , 2014, Molecular oncology.
[2] Ravi Radhakrishnan,et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.
[3] F. Berthold,et al. High genomic instability predicts survival in metastatic high-risk neuroblastoma. , 2012, Neoplasia.
[4] M. Irwin,et al. Transcript signatures that predict outcome and identify targetable pathways in MYCN‐amplified neuroblastoma , 2016, Molecular oncology.
[5] Jan Koster,et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.
[6] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Naranjo,et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[8] R. Wade,et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. , 2014, The Lancet. Oncology.
[9] A. Look,et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study , 2015, British Journal of Cancer.
[10] Antonio Ortega,et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. , 2006, Journal of the National Cancer Institute.
[11] S. Groshen,et al. Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis , 2017, Clinical Cancer Research.
[12] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Two independent epigenetic biomarkers predict survival in neuroblastoma , 2015, Clinical Epigenetics.
[14] A. Naranjo,et al. Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group , 2013, The Journal of Nuclear Medicine.
[15] C. R. Pinkerton,et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. , 1988, Progress in clinical and biological research.
[16] D. Zwijnenburg,et al. Abstract PR06: TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors , 2016 .
[17] K. Matthay,et al. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. , 2016, European journal of cancer.
[18] H. Lode,et al. Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival , 2016, Oncoimmunology.
[19] J. Vandesompele,et al. Individual patient risk stratification of high‐risk neuroblastomas using a two‐gene score suited for clinical use , 2015, International journal of cancer.
[20] Ji Won Lee,et al. ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor , 2017, Cancer research and treatment : official journal of Korean Cancer Association.
[21] A. Naranjo,et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1 , 2014, The Journal of Nuclear Medicine.
[22] Alexia Iasonos,et al. Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. , 2013, Gynecologic oncology.
[23] Ruth Ladenstein,et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. , 2009, The Lancet. Oncology.
[24] Gian Paolo Tonini,et al. An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma , 2016, Journal of Translational Medicine.
[25] W. Gregory,et al. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] K K Matthay,et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Bermúdez,et al. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients , 2016, Journal of Cancer Research and Clinical Oncology.
[28] Jinghui Zhang,et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.
[29] H. Koo,et al. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma , 2016, Cancer research and treatment : official journal of Korean Cancer Association.
[30] Ruth Ladenstein,et al. Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study , 2018, Pediatric blood & cancer.
[31] A. Naranjo,et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .
[32] A. Look,et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group , 2013, Cancer.
[33] T. Hocking,et al. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients , 2018, Journal of the National Cancer Institute.
[34] R. Arceci. Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project , 2012 .
[35] M. Pistillo,et al. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation. , 2016, Biochimica et biophysica acta.
[36] J. Maris,et al. Genetic susceptibility to neuroblastoma. , 2017, Current opinion in genetics & development.
[37] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[38] K. Jahnukainen,et al. Ultrahigh-risk Group Within the High-risk Neuroblastoma Category , 2013, Journal of pediatric hematology/oncology.
[39] G. Tonini,et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. , 2009, Cancer research.
[40] A. Naranjo,et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group , 2017, Cancer.
[41] A. Kaneda,et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. , 2005, Cancer research.
[42] M. Fischer,et al. Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients , 2017, Carcinogenesis.
[43] K. McHugh,et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Günter Schreier,et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. , 2017, The Lancet. Oncology.
[45] V. Pistoia,et al. Intratumoral diversity of telomere length in individual neuroblastoma tumors , 2014, Oncotarget.
[46] Simon C Watkins,et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma , 2015, Nature.
[47] Ching-Hon Pui,et al. Challenging issues in pediatric oncology , 2011, Nature Reviews Clinical Oncology.
[48] I. Ostrovnaya,et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] L. Zitvogel,et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients , 2015, Science Translational Medicine.
[50] N. Cheung,et al. Striking dichotomy in outcome of MYCN‐amplified neuroblastoma in the contemporary era , 2014, Cancer.
[51] Giovanni Cecchetto,et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Helen X. Chen,et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.
[53] F. Speleman,et al. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. , 2009, Cancer letters.
[54] Patrick Warnat,et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] D. Zwijnenburg,et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.
[56] F. Fang,et al. Using Multivariate Regression Model with Least Absolute Shrinkage and Selection Operator (LASSO) to Predict the Incidence of Xerostomia after Intensity-Modulated Radiotherapy for Head and Neck Cancer , 2014, PloS one.
[57] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[58] A. Naranjo,et al. Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials , 2017, Cancer.
[59] F. Berthold,et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Lorenzo Rosasco,et al. UvA-DARE ( Digital Academic Repository ) A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients , 2010 .
[61] S. Cialfi,et al. A sketch of known and novel MYCN-associated miRNA networks in neuroblastoma , 2017, Oncology reports.
[62] S. Navarro,et al. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort , 2016, British Journal of Cancer.
[63] M. Qayed,et al. Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma. , 2017, Journal of pediatric hematology/oncology.
[64] Cesare Furlanello,et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma , 2015, Oncoimmunology.
[65] R. Pieters,et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. , 2012, The American journal of pathology.
[66] Joseph T. Glessner,et al. Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci , 2011, PLoS genetics.
[67] Li Lin,et al. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification. , 2017, Biochimie.
[68] H. Juan,et al. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma , 2016, Oncotarget.
[69] W. London,et al. Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma: rs1800795 (Promoter) and rs8192284 (Receptor) , 2009, Clinical Cancer Research.
[70] Giovanni Parmigiani,et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.
[71] F. Berthold,et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] M. Berger,et al. Prioritization schema for immunotherapy clinical trials in glioblastoma , 2016, Oncoimmunology.
[73] Gudrun Schleiermacher,et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.